(Bloomberg) -- Denmark won't use Johnson & Johnson's Covid-19 vaccine in its immunization program, because the benefits don't outweigh the risk of blood clots, according to the country's health authority.
The suspension comes less than a month after Denmark became the first European Union member to drop AstraZeneca Plc for similar reasons. Monday's decision was first reported by the BT newspaper.
The Danish Health Authority said it took into account the current situation in Denmark where the virus is under relative control and most unvaccinated people are young and healthy.
Denmark had pre-ordered about 7 million vaccine shots from J&J, more than from any other producer. The decision to drop the company from its inoculation program delays the national vaccine rollout by four weeks, the health authority said. According to the previous schedule, all Danes would have been offered a vaccine by early August.
| Read more... |
|---|
©2021 Bloomberg L.P.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
